2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Usman Ali Akbar, MD, research coordinator, Division of Infectious Diseases, the University of Louisville, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).
This systematic review evaluated phase 2 and 3 clinical trials to observe the outcomes associated with the use of monoclonal antibodies compared with standard-of-care (SOC) chemotherapy in adult patients with ALL. A total of 1330 patients were included in the systematic review.
For example, 1 of the studies evaluated was the phase 3 iNNOVATE trial (NCT01564784), which evaluated inotuzumab (Besponsa) in patients with ALL, Akbar says. Data from this trial showed a complete response rate of 74% with inotuzumab vs 31% with SOC, Akbar explains.
Moreover, a total of 794 patients were evaluated from phase 2 trials, Akbar continues. Observations from those trials revealed that antibody-specific drugs, such as inotuzumab, epratuzumab (LymphoCide), and rituximab (Rituxan), performed better than SOC chemotherapy, Akbar concludes.